Topic Listing for Achillion Pharmaceuticals

Accrued Expenses Ach-1095 Ach-1625 Hcv
Ach-1095 Ns4a Antagonist Hcv Infection Ach-1095 Protease Inhibitor Series Hcv
Ach-1625 Ach-1095 Ach-2684 Hcv Ach-1625 Protease Inhibitor Chronic Hepatitis Infection
Ach-2684 High-potency Protease Inhibitor Hcv Infection Ach-702 Anti-mrsa Antibacterial
Ach-702 Anti-mrsa Antibiotic Ach-702 Drug Resistant Bacterial Infections
Achillion Achillion Announces Appointment New Chief Medical Officer
Achillion Announces Appointment New Head Business Development Achillion Announces License Agreement Elvucitabine Development China
Achillion Approach Ach-702 Achillion Approach Elvucitabine
Achillion Approach Hcv Protease Inhibitor Achillion Approach Hcv Protease Inhibitor Ach-1625
Achillion Approach High-potency Protease Inhibitor Ach-2684 Achillion Approach Ns4a Anatagonists
Achillion Approach Ns4a Antagonist Ach-1095 Achillion Elect Update Forward-looking Statements Some Point Future
Achillion Pharmaceuticals Inc Achillion Receives Notice Nasdaq
Achillion Regains Compliance Nasdaq Listing Rules Achillion Reports 2007 Financial Results
Achillion Reports 2007 Year-end Financial Results Achillion Reports 2008 Financial Results
Achillion Reports Results Adjustments Changes Common Stock Certain Other Events
Advances Amended Restated Employment Agreement
Amended Restated Investor Rights Agreement Amendment
Amendment Master Security Agreement Amendments
Annual Performance-based Cash Bonus Assignment Termination
Audit Committee Audit Committee Report
Auditors Fees Authorization Agreement Pre-arranged Payment Plan
Authorized Signatures Sign Here- Completed Vote Counted Date Background
Bacteria Base Salary
Basis Presentation Because Relative Weakness Chinese Legal System General Intellectual
Beneficial Ownership Reporting Compliance Board Committees
Board Determination Independence Board Meetings Attendance
Board Resolutions Broker Non-votes Abstentions
Business Substantial Risk Product Liability Claims Unable Obtain C-2
Capital Market Risk Currently Product Revenues Depend Funds Capital Stock
Capital Structure Cash Equivalents Restricted
Certain Relationships Related Transactions Certificate Delivery Installation
Certification Certification Pursuant Usc 1350 Adopted 906 Sarbanes-oxley Act
Change Vote Changes Internal Control Over Financial Reporting
Choice Law Jurisdiction Clinical Development History
Clinical Trials Drug Candidates Prolonged Delayed Unable Commercialize Code Business Conduct Ethics
Collaboration Arrangement Collaboration Arrangements
Collaboration Gilead Sciences Inc Collaboration License Agreement Gilead Sciences Inc
Collaboration Operations Collaborations Licenses
Collaborative Partner Terminates Fails Perform Obligations Agreements Development Collateral
Collateral Schedule 002 Collateral Schedule 003
Collateral Schedule 004 Commercial Product Support Activities
Commitments Common Stock
Common Stock Warrants Communicating Independent Directors
Comparison 2007 2006 Comparison 2008 2007
Comparison 2009 2008 Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Components Compensation Directors
Compensation Objectives Compensation Processes
Competition Compliance Irs Code 162
Compound Demonstrates Excellent Potency Against Hcv Retains Activity Compound Synthesis Hit Identification Lead Optimization
Comprehensive Income Loss Comprehensive Loss
Concentration Risk Conditions Advance Closing
Conduct Research Conference Call
Conference Call Held Friday 800 Conference Call Today 430pm
Confidentiality Confidentiality Agreements Employees Others Not Adequately Prevent Disclosure
Consent Independent Registered Public Accounting Firm Consent Waiver
Contact Contractual Obligations Commitments
Convertible Preferred Stock Corporate Governance Guidelines
Creation Security Interest Critical Accounting Policies Estimates
Critical Accounting Standards Estimates D-14 Adopted Pursuant 302 Sarbanes-oxley Act 2002
Data Date
Debt Default Remedies
Delivery Security Holder Documents Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Officers Election Appointment Principal Compensatory Depend Heavily Success Most Advanced Drug Candidate Elvucitabine
Depend Success Hcv Drug Candidates Ach-1095 Ach-1625 Still Depend Success Hcv Drug Candidates Ach-1095 Ach-1625 Well
Depend Success Hcv Drug Candidates Ach-1625 Ach-1095 Ach-2684 Depend Success Hcv Drug Candidates Ach-1625 Ach-1095 Still
Development Drug Substance Diligence
Director Compensation Director Nomination Process
Directors Directors Whose Terms Expire 2008 Class
Directors Whose Terms Expire 2009 Class Directors Whose Terms Expire 2010 Class
Directors Whose Terms Expire 2011 Class Discovery Programs
Dispute Resolution Dividends
Documents Incorporated Reference Dont Return Proxy
Drug Candidates Drug Candidates Still Early Stages Development Remain Subject
Drug Discovery Development Capabilities Drug Discovery Programs Capabilities
Each Outstanding Share Common Stock Entitled Vote Matter Earnings Loss Per Share Eps
Ecitals Effects Opt-in
Elizabeth Olek Elvucitabine
Elvucitabine Hiv Emory University
Employee Stock Purchase Plan Employees
Employment Agreements Potential Payments Termination Change Control Entry Material Definitive Agreement
Eport Independent Registered Public Accounting Firm Epresentations Arranties
Equipment Loan Advances Notes Conditions Precedent Contingency Creation Equity Awards
Equity Compensation Plan Information Equity Compensation Table
Equity-based Awards Erm Ermination
Estimates Evaluation Disclosure Controls Procedures
Evelopment Ommercialization Icense Greement Even Obtain Regulatory Approvals Drug Candidates Subject Ongoing
Exact Name Registrant Specified Charter Except Per Share Amounts
Exchange Rate Manner Place Payment Execution Copy
Executive Compensation Executive Officer Compensation Bonuses Equity Grants
Executive Officers Directors Principal Stockholders Own Large Percentage Executive Officers Registrant
Exhibits Fair Value Financial Instruments
Federal Legislation Increased Pressure Reduce Prices Pharmaceutical Products Fifth Amendment Master Security Agreement
Financial Guidance Financial Operations Overview
Financial Provisions Financial Results
Financial Results Conference Call Scheduled Financial Statements Exhibits
Fixed Assets Fob Synthesis Inc
Foreign Regulation Form 10-k
Form 10-q Form Bailee Consent
Form Proxy Card Former Name Address Changed Since Last Report
Forward-looking Statements Full-year Results
Further Assurances Gautam Shah Phd
Gca Therapeutics Ltd Gcat
Gcat Clinical Development Activities Gcats Right Bring Suit
General General Administrative
General Administrative Expenses General Provisions
George Street New Haven 06511 Gilead
Gilead Sciences Gilead Sciences Inc
Government Regulation Product Approval Grant License Exclusivity
Granted 2006 Stock Incentive Plan Grants Plan-based Awards
Grow Through Additional Acquisitions Dilute Existing Shareholders Involve Hallenge
Hcv Hcv Inhibitor Program
Held 2007 Held 2008
Held 2009 Here Withhold Vote Nominees
Hiv Capsid Program Hold Conference Call Discuss Results
Hold Meeting Holders Record
Householding Proxy Materials Icenses Ovenants
Important Notice Regarding Availability Proxy Materials Annual Meeting Income Taxes
Indemnification Index
Index Financial Statements Infringement Parties
Infringement Party Rights Initial Public Offering
Installment Amount 1288975 Insurance
Intellectual Property Intellectual Property Protection Related Matters
Introduction Investors
Issuance Series C-2 Convertible Preferred Stock Issuer Purchases Equity Securities
John Pottage Joseph Truitt
Landlord License Agreement
License Agreement Amendment License Patent Rights Third-party Owners Such Not Properly
License Research Development Agreements Limitations Current Therapies
Limited Operating History Incurred Cumulative Loss Since Inception Liquidity Capital Resources
Litigation Regarding Patents Patent Applications Other Proprietary Rights Loan Security Agreement
Long-lived Assets Long-term Debt
Managements Annual Report Internal Control Over Financial Reporting Manufacturing Supply
Market Information Market Subject Intense Competition Unable Compete Effectively Drug
Marketable Securities Marketable Securities Equity Investments
Mary Kay Fenton Master Security Agreement
Material Preclinical Research Clinical Development Media
Meeting Michael Kishbauch
Milestone Payments Milind Deshpande Phd
Miscellaneous Miscellaneous Provisions
Name Loan Party Name Person Filing Proxy Statement Other Registrant
Nature Business Ndemnification Nsurance Imitations Iability
Nicholas Simon Nited Tates Aws Egulations
Nominating Corporate Governance Committee Nominees Term Expiring 2010 Class Directors
Nominees Term Expiring 2011 Class Directors Nominees Term Expiring 2012 Class Directors
Non-disclosure Non-public Information Non-voting
Nondisclosure Obligation Not Able Advance Ach-1095 Human Clinical Development Program
Not Able Attract Retain Key Management Scientific Personnel Not Able Determine Most Appropriate Therapeutic Ach-702 Execute
Not Anticipate Paying Cash Dividends Accordingly Stockholders Rely Not Comply Laws Regulating Protection Environment Health Human
Not Comply Nasdaqs Listing Requirements Common Stock Delisted Not Successful Currently On-going Negotiations Collaboration Partner Gilead
Not Successful Forming Alliance Commercialization Elvucitabine Significantly Delayed Noted Address Changes Comments Above Please Corresponding Box
Notes Financial Statements Notice Exercise
Notice Stock Option Exercise Notices
Now Therefore Parties Hereto Agree Follows Certain Definitions Ns4a Antagonists Hcv
Ns4a Antagonists Hcv Infection Nspection Egulatory Uthority
Number 001-33095 Occasionally Grants Stock Option Awards Consultants Such Accounted
Off-balance Sheet Arrangements Officers
Ommercialization Ongoing Planned Clinical Development
Operating Leases Opt-in Right
Option Exercises Stock Vested Other Compensation
Other Current Assets Other Events
Other Income Expense Other License Research Development Agreements
Outstanding Equity Awards Overview
Overview Hcv Market Overview Hiv Market
Overview Hospital-based Antibacterials Market Part
Part Master Security Agreement Dated 2002 Contract Between Part Other Information
Patent Costs Permitted Disclosures
Pharmaceuticals Inc Debtor Phase
Physicians Patients Not Accept Future Drugs Unable Generate Policies Procedures Regarding Review Approval Ratification Related Person
Post-approval Requirements Considerations Pre-approval Policies Procedures
Preclinical Candidate Selection Preclinical Development History
Preferred Stock Prepaid Expenses Other Current Assets
Pricing Information Private Placement Financing
Proceeds Promissory
Proposal 1-election Class Directors Proposal 1-election Directors
Proposal 2-ratification Selection Independent Registered Public Accounting Firm Proposals Board Directors Recommends Vote Nominees Listed Proposal
Proposals Vote Director Nominees Proposal Number Recommended Board Prospectus Supplement Registration Statement Form S-3
Provides Incremental Funding Hcv Pipeline Development- Proxy Card Valid Only Signed Dated
Proxy Properly Executed Voted Directed Undersigned Stockholder Proxy Properly Executed Voted Directed Undersigned Stockholder Such
Proxy Solicited Board Directors Achillion Pharmaceuticals Inc Proxy Voted
Public Accounting Firm Public Offering
Publicity Names Purpose Annual Meeting
Pursuant 906 Sarbanes-oxley Act 2002 Quarterly Results
Quorum Recent Federal Legislation Increase Pressure Reduce Prices Pharmaceutical
Recent Financings Initial Public Offering Recently Completed Ongoing Clinical Development
Recently Issued Accounting Pronouncements Recently Issued Accounting Standards
Recently Reduced Staff Level Eliminated Certain Personnel Other Recitals
Reclassifications Record Date Shares Outstanding
Records Audit Records Reports
Registrants Telephone Number Including Area Code Registration Rights Agreement
Regulatory Regulatory Matters
Reimbursement Related Party
Related Party Transactions Rely Parties Conduct Clinical Trials Those Not Perform
Remainder Page Intentionally Left Blank Report Independent Registered Public Accounting Firm
Reports Reports Diligence
Representations Warranties Representations Warranties Covenants Debtor
Representations Warranties Investor Required Dilute Existing Stockholders Further Connection Capital Raising
Research Collaboration License Agreement Research Development
Research Development Expenses Research License Agreement
Research Program Restructuring Charges
Restructuring Plan Results
Results Operations Results Operations Financial Condition
Retirement Plan Revenue
Revenue Recognition Revenues
Revocability Proxies Revocation Proxies
Risks Related Business Risks Related Commercialization Drug Candidates
Risks Related Dependence Parties Risks Related Patents Licenses
Risks Relating Common Stock Royalties
Sales Marketing Sales Unregistered Equity Securities Proceeds
Sarbanes-oxley Act 2002 Schedule
Scientists Securities Authorized Issuance Equity Incentive Plans
Securities Purchase Agreement Securities Registered Pursuant Act
Segment Information Segment Reporting
Shall Construed Accordance Governed Laws State New York Share-based Payments
Signature Signature Page Follow
Signature Page Follows Signatures
Significant Portion Total Outstanding Shares Restricted Immediate Resale Solicitation Proxies
Soliciting Proxies Standby Equity Distribution Agreement
Stock Based Compensation Stock Incentive Plan
Stock Option Plan Stock Options Apb
Stock Options Sfas 123r Stock Price Likely Volatile Market Common Decline Value
Stock-based Compensation Stock-based Compensation Employee Awards
Stock-based Compensation Non-employee Awards Stock-based Compensation-employee Awards
Stock-based Compensation-non-employee Awards Stockholder Proposals 2008 Annual Meeting
Stockholder Proposals 2009 Annual Meeting Stockholder Proposals 2010 Annual Meeting
Strategy Subsections Hereby Added Existing Paragraph Now Identified Reads
Subsections Hereby Added Read Follows Subsections Through Xvii Hereby Added Read Follows
Subsequent Event Subsequent Events
Substantial Risks Associated Standby Equity Distribution Agreement Global Summary Compensation Table
Supplemental Severance Agreement Table Contents
Tabulation Target Selection Assay Development
Term Termination Termination Achillion
Termination Based Compensation Third-party Payors Not Adequately Reimburse Patients Drug Candidates
Trademarks Unable Adequately Protect Drug Candidates Infringe Rights Others
Unable Establish Sales Marketing Capabilities Enter Agreements Parties Unable Maintain Compliance Nasdaqs Listing Requirements Common Stock
Unable Meet Operational Legal Financial Challenges Encounter International Unable Obtain Foreign Regulatory Approval Commercialize Drug Candidates
Underwriters Over-allotment Option Unit Warrants
United States United States Drug Development Process
United States Review Approval Processes University Maryland Baltimore County
Unregistered Sales Equity Securities Unstable Market Economic Conditions Serious Adverse Consequences Business
Vion Pharmaceuticals Yale University Viruses
Voted Meeting Voting Instructions
Voting Proxies Annual Meeting Voting Proxy
Voting Shares Held Street Name Warrant Purchase 21368 Shares Common Stock
Warrants Whereas Subsidiary Borrower Benefit Making Loan Credit Facility
Xhibit 124 Lvucitabine Escription ~conference Call Begin 430 Eastern Time Today~
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki